US Judge Seeks Explanation for DOJ’s Decision to Drop Gautam Adani Bribery Case 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Iran Attack in Strait of Hormuz Pushes Oil Prices Higher 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern 
US Dollar Slips After PCE Inflation Data as Fed Rate Hike Expectations Stay Elevated 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Asian Stocks Sink as Apple Price Hikes Spark AI Valuation Fears, South Korea and Japan Lead Selloff 
Morgan Stanley Sees Chinese Auto Market Recovery Gaining Momentum in Late Summer 
Apple Supplier Stocks Slide as Samsung, SK Hynix Lead Selloff After Apple Price Hikes 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
US Dollar Slips After PCE Inflation Data Eases Fed Rate Hike Expectations 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
Nomura Stock Upgraded to Buy by BofA as Stronger ROE and Earnings Growth Boost Outlook 
Gold Drops Below $4,000 as Strong US Dollar and Fed Rate Hike Expectations Pressure Bullion 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Samsung Biologics, South Korea's biotech behemoth, expands its portfolio in a $1.08 billion deal with U.S. pharma titan, Pfizer, marking a landmark in global biotech manufacturing. The enhanced partnership will leverage Samsung's newest facility to produce Pfizer's multiproduct biosimilar portfolio.
This includes a new contract signed with Pfizer, building upon the initial deal established in March. Under the new agreement, Samsung Biologics will manufacture an additional $193 million of Pfizer products.
Additionally, Samsung Biologics will produce Pfizer's multiproduct biosimilar portfolio, encompassing oncology, inflammation, and immunotherapy, with a value of $704 million. The company will extend its manufacturing capabilities to provide Pfizer ample capacity for large-scale production of a multiproduct biosimilar portfolio.
This strategic collaboration will occur at Samsung Biologics' newest facility, Plant 4, in Songdo, South Korea. Completing the 240,000-liter biomanufacturing plant in June 2023 marks a significant milestone in the continued growth of Samsung Biologics.
Mike McDermott, Chief Global Supply Officer and Executive Vice President at Pfizer, expressed his enthusiasm for the partnership, stating they are pleased to extend the strategic collaboration with Pfizer as we share and support their strong vision to bring innovative solutions for patients around the globe.
These manufacturing partnerships solidify Samsung Biologics' position in the global contract development and manufacturing organization (CDMO) market. As part of its expansion strategy, the company is increasing its production capacity and aims to become a major player in the industry.
The contracts with Pfizer highlight the long-term strategic partnership between the two companies, further establishing Samsung Biologics as a trusted collaborator. The company plans to explore new avenues in overseas markets by considering opening new sales offices to facilitate communication with global customers. With an existing office in New Jersey and a research and development center in San Francisco, Samsung Biologics is set for continued growth on a global scale.
